Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 4/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702417 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL4078522 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29365434 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29371610 | 1.00 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29551697 | 0.96 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL29365163 | 0.96 | P2RY2 (0.61) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL8613676 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL8614074 | 0.95 | P2RY2 (0.62) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL15698310 | 0.95 | P2RY2 (0.56) | P2RY2P2RY4P2RY6POLBFUT5 | |
| SCHEMBL30839331 | 0.95 | P2RY2 (0.57) | P2RY2P2RY4P2RY6POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247200-B2 | Compositions and methods for generating massively parallel nucleic acid sequencing libraries | BIOO SCIENTIFIC CORPORATION (US) | 2025-03-11 | — | — | US | claimed |
| EP-4323501-A1 | GENETIC MODIFICATION OF HEPATOCYTES | Beam Therapeutics Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| CN-116381228-A | Reagent for capturing and detecting circulating exosomes and application thereof | 上海大学 | 2023-07-04 | — | — | CN | claimed |
| WO-2022221699-A1 | GENETIC MODIFICATION OF HEPATOCYTES | BEAM THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| CN-114667149-A | Novel nucleobase editor and methods of use | 比姆医疗股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| EP-4728067-A2 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | Beam Therapeutics Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4061961-B1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECH PLC (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696777-A1 | CAS13 PROTEIN, AND CRISPR-CAS SYSTEM AND USE THEREOF | Yoltech Therapeutics Co., Ltd (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4652277-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652278-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4034131-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | Brentano Biotechnology Associates (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220235361-A1 | RNAi Inhibition of Alpha-ENaC Expression | ARROWHEAD PHARMACEUTICALS INC (US) | 2022-07-28 | — | — | US | disclosed |
| EP-4028026-A1 | NOVEL NUCLEOBASE EDITORS AND METHODS OF USING SAME | Beam Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4022050-A2 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | Beam Therapeutics Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114667149-A | Novel nucleobase editor and methods of use | 比姆医疗股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220112505-A1 | RNAi Inhibition of Alpha-ENaC Expression | ARROWHEAD PHARMACEUTICALS INC (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | BRENTANO BIOTECHNOLOGY ASSOCIATES (US) | 2022-03-10 | — | — | US | disclosed |
| US-11268082-B2 | Nucleobase editors comprising nucleic acid programmable DNA binding proteins | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | P2RY2 2637/4885P2RY4 2341/4885P2RY6 2265/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | P2RY2 1969/4885P2RY4 1893/4885P2RY6 2458/4885 |
| US-11268082-B2 | Nucleobase editors comprising nucleic acid programmable DNA binding proteins | CNBP, DCLRE1B, APOBEC3C | P2RY2 2666/4885P2RY4 3240/4885P2RY6 2892/4885 |
| US-20220073546-A1 | DIASTEREOMERIC LINKING REAGENTS FOR NUCLEOTIDE PROBES | NCL, PCNA, DNTT | P2RY2 850/4885P2RY4 608/4885P2RY6 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.